843 reports of this reaction
1.4% of all CAFFEINE CITRATE reports
#14 most reported adverse reaction
SYSTEMIC LUPUS ERYTHEMATOSUS is the #14 most commonly reported adverse reaction for CAFFEINE CITRATE, manufactured by Hikma Pharmaceuticals USA Inc.. There are 843 FDA adverse event reports linking CAFFEINE CITRATE to SYSTEMIC LUPUS ERYTHEMATOSUS. This represents approximately 1.4% of all 60,859 adverse event reports for this drug.
Patients taking CAFFEINE CITRATE who experience systemic lupus erythematosus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SYSTEMIC LUPUS ERYTHEMATOSUS is a less commonly reported adverse event for CAFFEINE CITRATE, but still significant enough to appear in the safety profile.
In addition to systemic lupus erythematosus, the following adverse reactions have been reported for CAFFEINE CITRATE:
The following drugs have also been linked to systemic lupus erythematosus in FDA adverse event reports:
SYSTEMIC LUPUS ERYTHEMATOSUS has been reported as an adverse event in 843 FDA reports for CAFFEINE CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SYSTEMIC LUPUS ERYTHEMATOSUS accounts for approximately 1.4% of all adverse event reports for CAFFEINE CITRATE, making it a notable side effect.
If you experience systemic lupus erythematosus while taking CAFFEINE CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.